What is MS Phase 3 Daclizumab Study DECIDE?

Category: Others

false

See also: Daclizumab

NCT01064401 is a double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC HYP) versus Avonex® (interferon β 1a) in patients with relapsing-remitting MS. Other study names are 205MS301, 2009-012500-11.

No patients have reported taking MS Phase 3 Daclizumab Study DECIDE.
Last updated:
There are no evaluations for MS Phase 3 Daclizumab Study DECIDE.